BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 21147910)

  • 1. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors.
    Robbins CM; Tembe WA; Baker A; Sinari S; Moses TY; Beckstrom-Sternberg S; Beckstrom-Sternberg J; Barrett M; Long J; Chinnaiyan A; Lowey J; Suh E; Pearson JV; Craig DW; Agus DB; Pienta KJ; Carpten JD
    Genome Res; 2011 Jan; 21(1):47-55. PubMed ID: 21147910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
    Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
    Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies.
    Sun J; Liu W; Adams TS; Sun J; Li X; Turner AR; Chang B; Kim JW; Zheng SL; Isaacs WB; Xu J
    Prostate; 2007 May; 67(7):692-700. PubMed ID: 17342750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
    Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
    Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.
    Lonigro RJ; Grasso CS; Robinson DR; Jing X; Wu YM; Cao X; Quist MJ; Tomlins SA; Pienta KJ; Chinnaiyan AM
    Neoplasia; 2011 Nov; 13(11):1019-25. PubMed ID: 22131877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples.
    Trifonov V; Pasqualucci L; Dalla Favera R; Rabadan R
    BMC Syst Biol; 2013 Mar; 7():25. PubMed ID: 23531283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
    Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic analysis of Korean patients with advanced prostate cancer by use of a comprehensive next-generation sequencing panel and low-coverage, whole-genome sequencing.
    Kang M; Cho E; Jang J; Lee J; Jeon Y; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
    Investig Clin Urol; 2019 Jul; 60(4):227-234. PubMed ID: 31294131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-exome sequencing demonstrates recurrent somatic copy number alterations and sporadic mutations in specialized stromal tumors of the prostate.
    Pan CC; Tsuzuki T; Morii E; Fushimi H; Chen PC; Epstein JI
    Hum Pathol; 2018 Jun; 76():9-16. PubMed ID: 29258903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.
    Nientiedt C; Endris V; Jenzer M; Mansour J; Sedehi NTP; Pecqueux C; Volckmar AL; Leichsenring J; Neumann O; Kirchner M; Hoveida S; Lantwin P; Kaltenecker K; Dieffenbacher S; Gasch C; Hofer L; Franke D; Tosev G; Görtz M; Schütz V; Radtke JP; Nyarangi-Dix J; Hatiboglu G; Simpfendörfer T; Schönberg G; Isaac S; Teber D; Koerber SA; Christofi G; Czink E; Kreuter R; Apostolidis L; Kratochwil C; Giesel F; Haberkorn U; Debus J; Sültmann H; Zschäbitz S; Jäger D; Duensing A; Schirmacher P; Grüllich C; Hohenfellner M; Stenzinger A; Duensing S
    Urol Oncol; 2020 Jul; 38(7):637.e17-637.e27. PubMed ID: 32280037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas.
    Lassmann S; Weis R; Makowiec F; Roth J; Danciu M; Hopt U; Werner M
    J Mol Med (Berl); 2007 Mar; 85(3):293-304. PubMed ID: 17143621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines.
    Hermans KG; van Alewijk DC; Veltman JA; van Weerden W; van Kessel AG; Trapman J
    Genes Chromosomes Cancer; 2004 Mar; 39(3):171-84. PubMed ID: 14732919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer.
    Xia S; Kohli M; Du M; Dittmar RL; Lee A; Nandy D; Yuan T; Guo Y; Wang Y; Tschannen MR; Worthey E; Jacob H; See W; Kilari D; Wang X; Hovey RL; Huang CC; Wang L
    Oncotarget; 2015 Jun; 6(18):16411-21. PubMed ID: 25915538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational method for estimating DNA copy numbers in normal samples, cancer cell lines, and solid tumors using array comparative genomic hybridization.
    Abkevich V; Iliev D; Timms KM; Tran T; Skolnick M; Lanchbury JS; Gutin A
    J Biomed Biotechnol; 2010; 2010():. PubMed ID: 20706610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
    Jönsson G; Dahl C; Staaf J; Sandberg T; Bendahl PO; Ringnér M; Guldberg P; Borg A
    Oncogene; 2007 Jul; 26(32):4738-48. PubMed ID: 17260012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
    Liu W; Laitinen S; Khan S; Vihinen M; Kowalski J; Yu G; Chen L; Ewing CM; Eisenberger MA; Carducci MA; Nelson WG; Yegnasubramanian S; Luo J; Wang Y; Xu J; Isaacs WB; Visakorpi T; Bova GS
    Nat Med; 2009 May; 15(5):559-65. PubMed ID: 19363497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
    Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
    Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-resolution genomic and expression analyses of copy number alterations in breast tumors.
    Haverty PM; Fridlyand J; Li L; Getz G; Beroukhim R; Lohr S; Wu TD; Cavet G; Zhang Z; Chant J
    Genes Chromosomes Cancer; 2008 Jun; 47(6):530-42. PubMed ID: 18335499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
    Dawson NA; Zibelman M; Lindsay T; Feldman RA; Saul M; Gatalica Z; Korn WM; Heath EI
    Mol Cancer Ther; 2020 Jun; 19(6):1373-1382. PubMed ID: 32220973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.